Dark

ATOS
Atossa Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jul 30, 2026 3:59:28 PM EDT

2.21USD-4.329%(-0.10)4,766

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 31, 2026 8:38:30 AM EDT

2.22USD+0.452%(+0.01)3,651

After-hours

Jul 27, 2026 4:00:30 PM EDT

2.36USD-1.461%(-0.03)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 27, 2022

09:30AM EST Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders: GlobeNewswire Inc

Jan 18, 2022

09:32AM EST Atossa Therapeutics Announces Advancement To Part B Of Clinical Study Of AT-H201 Benzinga

09:30AM EST Atossa Therapeutics Announces Advancement to Part B GlobeNewswire Inc

Dec 22, 2021

09:31AM EST Atossa Genetics Reports Begins Enrollment Of Phase 2 Study Of Oral Endoxifen In Sweden Benzinga

09:30AM EST Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of GlobeNewswire Inc

Dec 16, 2021

09:02AM EST Physician-Scientist Steven Quay Calls for International Effort to Investigate a PR Newswire

Dec 6, 2021

09:18AM EST Atossa Therapeutics Completes Pre-IND Meeting With FDA On Z-Endoxifen Benzinga

09:15AM EST Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & GlobeNewswire Inc

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 24, 2021

09:30AM EST Registration Is Now Open For The Tribe Public Webinar Event On GlobeNewswire Inc

Nov 15, 2021

09:30AM EST Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments. GlobeNewswire Inc

Oct 21, 2021

09:30AM EDT Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of GlobeNewswire Inc

Sep 30, 2021

09:34AM EDT Atossa Therapeutics Begins Enrollment In Clinical Study Of AT-H201 In Australia Benzinga

09:30AM EDT Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 GlobeNewswire Inc

Sep 15, 2021

09:45AM EDT Atossa Therapeutics Option Alert: Oct 15 $3.5 Calls Sweep (12) near the Ask: 1000 @ $0.4 vs 4421 OI; Earnings 11/12 Before Open [est] Ref=$3.3694 Benzinga

Sep 10, 2021

07:36PM EDT Atossa Therapeutics Option Alert: Oct 15 $4 Calls Sweep (24) near the Ask: 1002 @ $0.448 vs 6692 OI; Ref=$3.8199 Benzinga

Sep 7, 2021

05:27PM EDT Atossa Therapeutics Adjourns Special Stockholder Meeting To October 7, 2021 To Allow Additional Time To Vote Benzinga

05:20PM EDT Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor GlobeNewswire Inc

Sep 2, 2021

09:31AM EDT Atossa Therapeutics Reports Approval From Swedish Ethics Review Authority To Initiate Phase 2 Study Of Oral Endoxifen To Reduce Mammographic Breast Density Benzinga

09:30AM EDT Atossa Therapeutics Receives Approval from the Swedish Ethics GlobeNewswire Inc

Aug 13, 2021

09:30AM EDT Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2021, and provides an update on recent company developments. GlobeNewswire Inc

Aug 4, 2021

10:21AM EDT Atossa Therapeutics Option Alert: Aug 20 $2.5 Calls Sweep (44) above Ask!: 7974 @ $1.024 vs 10446 OI; Earnings 8/16 Before Open [est] Ref=$3.2708 Benzinga

10:14AM EDT Atossa Therapeutics Option Alert: Sep 17 $4 Calls Sweep (10) near the Ask: 900 @ $0.4 vs 10449 OI; Earnings 8/16 Before Open [est] Ref=$3.045 Benzinga

Jul 26, 2021

09:01AM EDT Virology COVID-19 patient specimens from December 2019 reveals extensive laboratory contamination, including evidence of genetic manipulation of the Nipah Virus, a BSL-4 pathogen more lethal than Ebola PR Newswire

Jul 23, 2021

12:37PM EDT Atossa Therapeutics Option Alert: Fri $4.5 Calls Sweep (41) near the Ask: 1000 @ $0.301 vs 4873 OI; Earnings 8/12 Before Open [est] Ref=$4.4 Benzinga

12:36PM EDT Atossa Therapeutics Option Alert: Fri $3.5 Calls Sweep (56) near the Ask: 1101 @ $1.049 vs 309 OI; Earnings 8/12 Before Open [est] Ref=$4.45 Benzinga

12:15PM EDT Atossa Therapeutics Option Alert: Fri $4 Calls Sweep (33) near the Ask: 1000 @ $0.4 vs 7057 OI; Earnings 8/12 Before Open [est] Ref=$4.25 Benzinga

12:03PM EDT Atossa Therapeutics Option Alert: Fri $3.5 Calls Sweep (24) near the Ask: 404 @ $0.7 vs 309 OI; Earnings 8/12 Before Open [est] Ref=$4.1 Benzinga

11:27AM EDT Atossa Therapeutics Option Alert: Fri $3.5 Calls Sweep (39) near the Ask: 1028 @ $0.5 vs 309 OI; Earnings 8/12 Before Open [est] Ref=$3.94 Benzinga

11:00AM EDT Atossa Therapeutics Option Alert: Fri $3.5 Calls Sweep (29) near the Ask: 782 @ $0.401 vs 309 OI; Earnings 8/12 Before Open [est] Ref=$3.85 Benzinga

Jul 21, 2021

10:12AM EDT Atossa Therapeutics Option Alert: Aug 6 $3 Calls Sweep (22) near the Ask: 1404 @ $1.5 vs 3535 OI; Earnings 8/12 Before Open [est] Ref=$4.33 Benzinga

Jul 15, 2021

09:04AM EDT Physician-Scientist Steven Quay And Investigators Provide Science-Based Analysis Of Origin Of COVID-19 To US Congress RTTNews

09:04AM EDT Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress PR Newswire

Jul 7, 2021

09:45AM EDT Atossa Therapeutics Option Alert: Jul 16 $7.5 Calls Sweep (27) near the Ask: 500 @ $0.6 vs 59411 OI; Earnings 8/12 Before Open [est] Ref=$6.0364 Benzinga

09:32AM EDT Atossa Therapeutics Reports Received Regulatory Approval To Open Clinical Study Of AT-H201 In Australia Benzinga

09:30AM EDT Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and Long Haul patients with post-infection pulmonary disease GlobeNewswire Inc

Jun 30, 2021

03:53PM EDT Atossa Therapeutics Option Alert: Jul 16 $12 Calls Sweep (24) near the Ask: 666 @ $0.45 vs 50618 OI; Earnings 8/12 Before Open [est] Ref=$6.255 Benzinga

09:43AM EDT Atossa Therapeutics Option Alert: Jan 21 $8 Calls Sweep (16) near the Ask: 500 @ $2.701 vs 1020 OI; Earnings 8/12 Before Open [est] Ref=$6.49 Benzinga

Jun 29, 2021

11:27AM EDT Atossa Therapeutics Option Alert: Aug 20 $16 Calls Sweep (14) near the Ask: 450 @ $1.153 vs 1647 OI; Earnings 8/12 Before Open [est] Ref=$7.45 Benzinga

Jun 28, 2021

07:50AM EDT Cramer Gives His Opinion On Carlotz, MannKind And More Benzinga

Jun 25, 2021

03:38PM EDT Atossa Therapeutics Option Alert: Jul 16 $14 Calls Sweep (11) near the Ask: 200 @ $1.401 vs 13568 OI; Earnings 8/12 Before Open [est] Ref=$8.2601 Benzinga

10:51AM EDT Atossa Therapeutics Option Alert: Jul 16 $12 Calls at the Ask: 627 @ $2.4 vs 50985 OI; Earnings 8/12 Before Open [est] Ref=$9.2489 Benzinga

10:28AM EDT Atossa Therapeutics Option Alert: Oct 15 $10 Calls Sweep (10) near the Ask: 333 @ $4.101 vs 3846 OI; Earnings 8/12 Before Open [est] Ref=$9.4999 Benzinga

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 24, 2021

12:09PM EDT Atossa Therapeutics Option Alert: Oct 15 $12 Calls Sweep (14) near the Ask: 210 @ $2.95 vs 1754 OI; Earnings 8/12 Before Open [est] Ref=$8.1365 Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

04:44AM EDT 44 Biggest Movers From Yesterday Benzinga

Jun 22, 2021

01:11PM EDT Atossa Therapeutics Option Alert: Jul 16 $12 Calls Sweep (6) near the Ask: 329 @ $1.576 vs 22250 OI; Earnings 8/12 Before Open [est] Ref=$7.29 Benzinga

12:53PM EDT Atossa Therapeutics Option Alert: Jul 16 $12 Calls Sweep (3) near the Ask: 200 @ $1.5 vs 22250 OI; Earnings 8/12 Before Open [est] Ref=$7.2782 Benzinga

12:32PM EDT Atossa Therapeutics Option Alert: Jul 16 $12 Calls Sweep (7) above Ask!: 200 @ $1.258 vs 22250 OI; Earnings 8/12 Before Open [est] Ref=$6.938 Benzinga

Jun 16, 2021

09:08AM EDT Atossa Therapeutics To Be Included In Russell 2000, 3000 Indices, Effective Jun. 28 Benzinga

09:00AM EDT Atossa Therapeutics Set to Be Included in the Russell 2000 and GlobeNewswire Inc

Jun 11, 2021

09:03AM EDT Atossa Therapeutics Receives Approval From Swedish Regulators To Initiate Phase 2 Clinical Study Of Oral Endoxifen To Reduce Mammographic Breast Density Benzinga

09:00AM EDT Atossa Therapeutics Receives Approval from Swedish Regulators to GlobeNewswire Inc

Jun 9, 2021

01:29PM EDT Atossa Therapeutics Reveals Final Endoxifen Data From Mid-Stage Breast Cancer Trial Benzinga

09:50AM EDT Atossa Therapeutics Option Alert: Jul 16 $9 Calls Sweep (6) near the Ask: 300 @ $1.3 vs 47577 OI; Ref=$5.74 Benzinga

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

09:10AM EDT Atossa Therapeutics Announces Final Data From Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction In Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated Benzinga

09:00AM EDT Atossa Therapeutics Announces Final Data fromPhase 2 GlobeNewswire Inc

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 7, 2021

09:01AM EDT Atossa Therapeutics To Release Final Data From Phase 2 Study Of Endoxifen Administered To Breast Cancer Patients Prior To Surgery At Webinar at 8 a.m. PT June 9 Benzinga

09:00AM EDT Atossa Therapeutics to Release Final Data from Phase 2 Study of GlobeNewswire Inc

Jun 4, 2021

09:43AM EDT Atossa Therapeutics Option Alert: Jul 16 $9 Calls Sweep (8) near the Ask: 308 @ $1.0 vs 45526 OI; Ref=$4.7689 Benzinga

May 27, 2021

01:31PM EDT New Research Demonstrates Claims that the Wuhan Institute of Virology had no PR Newswire

May 21, 2021

09:01AM EDT Atossa Therapeutics CEO To Participate In May 24 Virtual Meeting To 'Brief the U.S. Congress On His Research Investigating the Origin of the COVID-19 Pandemic' Benzinga

09:01AM EDT Physician-Scientist Dr. Steven Quay to Brief the U.S. Congress On His Research PR Newswire

May 14, 2021

09:16AM EDT Atossa Genetics Q1 EPS $(0.04) Up From $(0.32) YoY Benzinga

09:15AM EDT Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2021, and provides an update on recent company developments. GlobeNewswire Inc

09:00AM EDT Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021. GlobeNewswire Inc

May 11, 2021

09:30AM EDT Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases urges stockholders to vote on proposals put forth in the proxy statement prior to the Companys May 14, 2021 annual stockholder meeting. GlobeNewswire Inc

May 6, 2021

03:52PM EDT Atossa Therapeutics Option Alert: Jul 16 $5.5 Calls Sweep (3) near the Ask: 974 @ $0.784 vs 1792 OI; Earnings 5/17 Before Open [est] Ref=$2.325 Benzinga

May 5, 2021

02:01PM EDT Atossa Therapeutics Option Alert: May 21 $5.5 Calls Sweep (15) near the Ask: 1000 @ $0.35 vs 1704 OI; Earnings 5/17 Before Open [est] Ref=$2.4805 Benzinga

Apr 30, 2021

09:31AM EDT Atossa Therapeutics Reports Its CEO Will Participate In Panel Discussion At Cello Health's Cancer Progress Virtual Conference May 6, 2021 Benzinga

09:30AM EDT Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel GlobeNewswire Inc

Apr 28, 2021

12:42PM EDT Atossa Therapeutics Option Alert: Jan 21 $2.5 Calls Sweep (14) near the Ask: 433 @ $1.0 vs 4343 OI; Earnings 5/12 Before Open [est] Ref=$2.255 Benzinga

12:04PM EDT Atossa Therapeutics Option Alert: May 21 $2 Calls Sweep (30) near the Ask: 823 @ $0.5 vs 4295 OI; Earnings 5/12 Before Open [est] Ref=$2.21 Benzinga

11:58AM EDT Atossa Therapeutics Option Alert: Oct 15 $6 Calls Sweep (26) near the Ask: 1000 @ $0.45 vs 416 OI; Earnings 5/12 Before Open [est] Ref=$2.12 Benzinga

Apr 21, 2021

04:49PM EDT Atossa Therapeutics Inc Files For Shelf Of Up To 13M Shares Of Common Stock By Selling Stockholders Benzinga

Apr 8, 2021

09:31AM EDT Atossa Therapeutics Reports Ovarian Cancer Patient Has Begun Treatment With Oral Endoxifen Under FDA's Expanded Access Pathway Benzinga

09:30AM EDT Atossa Therapeutics Announces Ovarian Cancer Patient has Begun GlobeNewswire Inc

Mar 31, 2021

09:32AM EDT Atossa Therapeutics FY 2020 EPS $(1.97) Vs $(2.03) YoY Benzinga

09:30AM EDT Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announced financial results for the fiscal year ended December 31, 2020, and provided an update on recent company developments. GlobeNewswire Inc

Mar 30, 2021

09:41AM EDT Physician-Scientist Steven Quay Provides Open Letter Response to WHO Report: PR Newswire

Mar 22, 2021

08:33AM EDT Atossa Therapeutics Announces Pricing Of $50M Registered Direct Offering Priced At-The-Market Benzinga

08:30AM EDT Atossa Therapeutics Announces Pricing of $50.0 Million Registered GlobeNewswire Inc

Mar 11, 2021

10:30AM EST Atossa Therapeutics Gets FDA Safe To Proceed Letter For Treatment Of An Ovarian Cancer Patient With Oral Endoxifen RTTNews

09:31AM EST Atossa Therapeutics Reports Receipt Of Safe To Proceed Letter For Its Ovarian Cancer Treatment Benzinga

09:30AM EST Atossa Therapeutics Announces Receipt of FDA Safe to Proceed GlobeNewswire Inc

Feb 25, 2021

11:15AM EST Atossa Therapeutics' COVID-19 Nasal Spray Safe In Early-Stage Study Benzinga

09:14AM EST Atossa Therapeutics Reports Final Results From Phase 1 Study Showing Safety, Tolerability Of AT-301 Nasal Spray Being Developed for COVID-19 Benzinga

09:00AM EST Atossa Therapeutics Announces Final Results from Phase 1 Clinical GlobeNewswire Inc

Feb 10, 2021

09:32AM EST Atossa Therapeutics President And CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Benzinga

09:30AM EST Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical needs in oncology and infectious diseases, with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders: GlobeNewswire Inc

Feb 3, 2021

09:31AM EST Atossa Therapeutics Announces Two-Year Update Of FDA-Approved Expanded Access Treatment With Endoxifen Benzinga

09:30AM EST Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or compassionate use) single-patient studies of Atossas Endoxifen. GlobeNewswire Inc

Feb 2, 2021

09:31AM EST Atossa Therapeutics Says Phase 2 Endoxifen Breast Cancer Study Produces 'Substantially Positive Results' Allowing Study To Be Halted Early Benzinga

09:30AM EST Atossa Therapeutics Phase 2 Endoxifen Breast GlobeNewswire Inc

Jan 29, 2021

09:31AM EST Atossa Reports $21M From Recent Exercises Of Outstanding Warrants Benzinga

09:30AM EST Atossa Therapeutics Receives $21 Million from Recent Exercises of GlobeNewswire Inc

08:01AM EST New Study By Dr. Steven Quay Concludes that SARS-CoV-2 Came from a Laboratory PR Newswire

Jan 27, 2021

09:00AM EST Registration Is Now Open For Tribe Publics GlobeNewswire Inc

05:29AM EST Pre-market Movers In Healthcare Sector: TMBR, AEZS, SRNE, RTTNews

Jan 26, 2021

10:38AM EST Atossa Therapeutics Shares Spike To Session High Over Last 30 Mins; Co. Pres, CEO To Speak As Panelist At 2021 Precision Medicine World Conference Today At 2:30 p.m. EST Benzinga

05:44AM EST Atosa Therapeutics Shares Trading Up 26% @$3.78 Premarket; Co CEO is Speaking Tuesday at 2:30 PM ET at Precision Medicine World Conference Benzinga

Jan 25, 2021

09:30AM EST Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak GlobeNewswire Inc

Jan 22, 2021

04:17PM EST Atossa Therapeutics Files Prospectus Relating To Sale Of Up To 10.5M Shares Of Common Stock By Selling Stockholders Shares Benzinga

Jan 15, 2021

11:46AM EST Atossa Therapeutics Amended 13G Filing From CVI Investments Shows 4.9% Stake Benzinga

Jan 8, 2021

06:02AM EST COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 PR Newswire

Jan 7, 2021

08:59AM EST French IT consulting group Atos confirmed that it has approached DXC Technology Co. (DXC) regarding a potential friendly transaction between the companies. RTTNews

Jan 6, 2021

09:16AM EST Atossa Therapeutics Announces Pricing Of $25.2M Offering Benzinga

09:15AM EST Atossa Therapeutics Announces Pricing of $25.2 Million Registered GlobeNewswire Inc

Dec 17, 2020

09:18AM EST Atossa Therapeutics Announces Pricing of $14M Registered Direct Offering Priced $1/Share Benzinga

09:15AM EST Atossa Therapeutics Announces Pricing of $14.0 Million Registered GlobeNewswire Inc

Dec 9, 2020

02:55PM EST Mid-Afternoon Market Update: Nasdaq Tumbles 2%; DoorDash Shares Spike Higher Benzinga

12:23PM EST Mid-Day Market Update: Dow Drops Over 100 Points; Rocket Pharmaceuticals Shares Jump Benzinga

Dec 8, 2020

09:45PM EST Atossa Therapeutics Announces Pricing of $20.0 Million GlobeNewswire Inc

Nov 13, 2020

09:33AM EST Atossa Genetics Q3 EPS $(0.34) Up From $(0.36) YoY Benzinga

09:30AM EST Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the third quarter ended September 30, 2020, and provided an update on recent company developments. GlobeNewswire Inc

Nov 10, 2020

10:06AM EST Atossa : Preliminary Phase 1 Study Shows Safety And Tolerability Of AT-301 Nasal Spray Being Developed For COVID-19 RTTNews

09:31AM EST Atossa Therapeutics Reports Prelim. Results From Phase 1 Study Showing Safety, Tolerability Of AT-301 Nasal Spray Being Developed For COVID-19 Benzinga

09:30AM EST Atossa Therapeutics Announces Preliminary Results from Phase 1 GlobeNewswire Inc

Oct 28, 2020

07:03AM EDT New Research Points to the People's Liberation Army Hospital in Wuhan, China as PR Newswire

Oct 19, 2020

10:16AM EDT Atossa Completes Enrollment Of Phase 1 Study Of AT-301 Nasal Spray Being Developed For Coronavirus Causing COVID RTTNews

09:31AM EDT Atossa Therapeutics Completes Enrollment Of Phase 1 Clinical Study Of AT-301 Nasal Spray Being Developed For Coronavirus Benzinga

09:30AM EDT Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study GlobeNewswire Inc

Oct 7, 2020

09:30AM EDT Registration Is Now Open For Atossa Therapeutics GlobeNewswire Inc

Oct 2, 2020

09:21AM EDT Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family PR Newswire

Sep 21, 2020

06:09PM EDT Atossa Therapeutics To Present at the Oppenheimer & Co. Fall GlobeNewswire Inc

Sep 17, 2020

11:18AM EDT Why Atossa Therapeutics Stock Is Trading Higher Today Benzinga

09:50AM EDT Atossa Reports Second Favorable Safety Review In Clinical RTTNews

09:39AM EDT Atossa Receives Second Positive Interim Safety Assessment In Study Of AT-301 Nasal Spray RTTNews

09:31AM EDT Atossa Genetics Reports Receives Second Positive Interim Safety Assessment In Study Of AT-301 Nasal Spray Being Developed For Coronavirus Causing COVID Benzinga

09:30AM EDT Atossa Therapeutics Receives Second Positive Interim Safety GlobeNewswire Inc

05:37AM EDT Ascendiant Capital Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $7 Benzinga

Sep 14, 2020

08:01AM EDT Physician-Scientist Dr. Steven Quay's "Stay Safe: A Physician's Guide to PR Newswire

Sep 8, 2020

08:01AM EDT Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and PR Newswire

Sep 1, 2020

09:34AM EDT Atossa Therapeutics Shares Move Higher After Co Announces Positive Interim Safety Assessment For Coronavirus Nasal Spray; Co Says Positive Assessment By Safety Committee Allows Study To Now Enroll Next Cohort Of Patients Benzinga

09:32AM EDT Atossa Therapeutics Announces Positive Interim Safety Assessment Of First Group Of Participants In Clinical Study Of AT-301 Nasal Spray Being Developed For Coronovirus Benzinga

09:30AM EDT Atossa Therapeutics Announces Positive Interim Safety Assessment GlobeNewswire Inc

Aug 26, 2020

09:30AM EDT Atossa Therapeutics to Present at the LD Micro 500 Virtual GlobeNewswire Inc

Aug 17, 2020

09:32AM EDT Atossa Therapeutics Announces Enrollment, Dosing Completed In First Group Of Healthy Participants In Clinical Study Of AT-301 Nasal Spray Being Developed For Treatment Of Coronavirus Benzinga

09:30AM EDT Atossa Therapeutics Announces Enrollment and Dosing Completed in GlobeNewswire Inc

Aug 13, 2020

09:32AM EDT Atossa Genetics Q2 EPS $(0.43) Up From $(0.80) YoY Benzinga

09:30AM EDT Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the second quarter ended June 30, 2020, and provided an update on recent company developments. GlobeNewswire Inc

Aug 3, 2020

09:43AM EDT Atossa Gets Australian Govt Approval To Open Clinical Study Of AT-301 Nasal Spray Being Developed To Treat COVID-19 RTTNews

09:40AM EDT Atossa Therapeutics Receives Approval To Open Clinical Study Of AT-301 Nasal Spray Being Developed To Treat Coronavirus Benzinga

09:30AM EDT Atossa Therapeutics Receives Approval to Open Clinical Study of GlobeNewswire Inc

Jul 30, 2020

09:34AM EDT Atossa Reports Interim Findings Following 18 Months Of Expanded Access Study Of Endoxifen RTTNews

09:33AM EDT Atossa Therapeutics Highlights Findings From Expanded Access Treatment With Endoxifen: 'Patient has taken Atossa's Endoxifen for 18 months without side effects and without cancer recurrence' Benzinga

09:30AM EDT Atossa Therapeutics Announces Findings from FDA-Approved Expanded GlobeNewswire Inc

Jul 27, 2020

09:30AM EDT Registration Is Now Open for Atossa Therapeutics GlobeNewswire Inc

Jul 22, 2020

05:37AM EDT Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program Benzinga

Jul 16, 2020

12:49PM EDT Atossa Genetics Shares Spike To Afternoon High Over $4 Level, Now Up 4.5%, As Hearing Maxim Raises Price Target From $4 To $8 Benzinga

10:18AM EDT Why Atossa Therapeutics Is Trading Lower Today Benzinga

10:09AM EDT Atossa Therapeutics shares are trading higher after the company announced it has contracted with Avance Clinical to conduct a clinical study for its AT-301 Nasal Spray for the company's second coronavirus therapeutics development program. Benzinga

09:16AM EDT Atossa Therapeutics Contracts For Clinical Study Of AT-301 Nasal Spray, Atossa's Second Coronavirus Therapeutic Development Program Benzinga

09:15AM EDT Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal GlobeNewswire Inc

Jul 15, 2020

10:09AM EDT Atossa Announces Successful Results From In Vitro Testing Of AT-301, Proprietary COVID-19 Nasal Spray Drug Candidate RTTNews

09:33AM EDT Atossa Therapeutics Shares Halted On Circuit Breaker, Up 12%, Following Co. Press Release Highlighting Successful In Vitro Testing Of Nasal Spray Formulation Benzinga

09:30AM EDT Atossa Therapeutics Announces Successful In Vitro Testing of Nasal GlobeNewswire Inc